What AIM Biotech does

AIM Biotech Pte. Ltd. is a Singapore-based private life-sciences tools company founded in 2012 that develops and sells microphysiological systems (MPS) and organ-on-a-chip platforms for humanized in vitro drug discovery. The company's core technology — microfluidic chips and plates that co-culture multiple cell types in discrete 3D and 2D channels — originated from MIT research by co-founder Dr. Roger Kamm and is commercialized under the idenTx family (3, 9, and 40 simultaneous-experiment formats) and the organiX platform for organoid and biopsy culture. Cell Systems products (AngioPrime, VasQ Kit, BBBBoost) provide standardized, human-relevant vascular and blood-brain barrier models integrated with the chip platforms. The technology is validated by over 140 peer-reviewed publications and has been adopted by named users including Dana-Farber Cancer Institute and Brigham and Women's Hospital for immuno-oncology and vascular biology research.

The company operates a dual revenue model. Product sales — including idenTx chips and plates (priced $570-$2,220 per box) and cell systems ($750-$2,560 per kit) — are sold directly through the company's e-commerce storefront and a global distributor network, with exclusive distribution arrangements in South Korea. A contract research services (CRO) arm provides pharma and biotech clients with custom assay development, high-content screening, and functional immuno-oncology studies conducted in AIM Biotech's own research lab. Distribution is reinforced by strategic technology integrations with Opentrons (OT-2 lab automation) and Nikon (AX confocal imaging), which embed AIM platforms into established pharma screening workflows. Target customers span bio-pharma companies seeking alternatives to animal testing and academic researchers in immuno-oncology, vascular biology, and neurobiology. The company is led by CEO Jim McGorry alongside founder and executive director Kuan Chee Mun, with co-founder Dr. Roger Kamm providing ongoing scientific leadership.

Name

AIM Biotech

Legal name

AIM Biotech Pte. Ltd.

Website

https://aimbiotech.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

AIM Biotech is a Singapore-based life-sciences tools company that develops microfluidic organ-on-a-chip platforms (idenTx, organiX) and standardized cell systems for humanized in vitro drug discovery, serving bio-pharma companies and academic researchers in immuno-oncology, vascular biology, and neurobiology.

Ownership category

akta.pro rank

Product category

Organ-on-chip / Microphysiological Systems

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Organ-on-chip platforms
• Microfluidic cell culture
• Drug discovery tools
• 3D tissue models
• Microphysiological systems

Headquarters

HQ city

Bukit Merah

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Product Sales: Sale of microfluidic chips and plates including idenTx 3, idenTx 9, and idenTx 40 plate formats, along with cell system products like AngioPrime and VasQ Kit. Products are sold directly through the website and through a global distributor network.
2. Contract Research Services: Full-service contract research offerings for pharma companies, combining speed and simplicity with complex tissue modeling. Services include custom assay development, rapid humanized throughput screening, functional immuno-oncology assays, and in vitro organ models. State-of-the-art research services lab delivers human-focused, clinically-relevant results.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

AIM Biotech designs and manufactures microfluidic chips and plates (idenTx 3, 9, and 40 formats) along with the organiX platform for culturing human organoids and biopsies, and standardized cell systems (AngioPrime, VasQ Kit, BBBBoost) for vascular and blood-brain barrier modeling. The company also provides contract research services that leverage these humanized 3D in vitro platforms to support drug discovery, immuno-oncology, vascular biology, and neurobiology research for pharma and biotech customers.

Product overview

AIM Biotech offers a portfolio of humanized 3D microfluidic platforms and cell systems for drug discovery and precision medicine. The core product lines include idenTx (organ-on-a-chip chips and plates in 3, 9, and 40 experiment formats) and organiX (organoid and biopsy culture platform). These are complemented by Cell Systems products including AngioPrime, VasQ Kit, and BBBBoost for specialized vascular and blood-brain barrier models. AIM Biotech also provides contract research services leveraging these platforms for pharma and biotech clients. The company was founded on technology developed at MIT by Dr. Roger Kamm and supports research across cancer, immuno-oncology, vascular biology, and neurobiology.

Differentiator

Problem solved

Functional benefit

Products and services

• idenTx 3 Chip Microfluidic 3D cell culture chip with a 3-channel design and central gel region, enabling 3 simultaneous experiments per chip. Microscope slide format compatible with standard lab equipment, polymerizable hydrogels, and phase contrast, fluorescence, and confocal microscopy.
• idenTx 9 Plate SBS-format plate with three integrated idenTx 3 Chips, enabling 9 simultaneous experiments. Supports scale-up for plate-based robotics and laboratory automation while maintaining the ease-of-use of the idenTx chip family.
• idenTx 40 Plate Highest throughput organ-on-a-chip platform, accommodating 40 independent experiments in standard SBS plate format. Designed for high-content screening and drug discovery at scale, compatible with existing laboratory automation workflows.
• organiX

Quantifiable outcome

• Over 140 peer-reviewed publications validating the technology across multiple research domains
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Nikon CorporationcoreStrategic or Co-development Partner · 25 May 2022Nikon Corporation selected AIM Biotech as one of the select organ-on-a-chip (OOAC) providers to support Nikon's expanding global contract research services for drug discovery. The partnership demonstrates the effectiveness of OOAC approaches, particularly AIM's idenTx platform, for accelerating drug discovery through human microphysiology recapitulation. AIM and Nikon scientists have optimized experimental conditions for using Nikon AX confocal microscope with idenTx 9 Plate for evaluating CAR-T cell dynamics in tumor microenvironments.
• OpentronscoreTechnology or IntegrationAIM Biotech partnered with Opentrons to implement automated drug discovery on in vitro platforms using the OT-2 lab robot. AIM's Applications Team utilized Opentrons Protocol Designer to create custom protocols for automating fluid handling including collagen gel preparation, media channel hydration and coating, cell seeding, medium changes, and cell staining. This automation enables scaling from basic to complex human cell-based assays for drug discovery.
• MatTekminorStrategic or Co-development PartnerPartnership on advanced 3D tissue culture organ-on-a-chip systems combining MatTek's expertise in tissue models with AIM Biotech's microfluidic platforms.
• Exclusive South Korea DistributorscoreChannel Partner/ Reseller/ DistributorExclusive distribution arrangement for South Korean market. The company explicitly states they do not accept orders for South Korea directly, requiring orders to be placed through exclusive distributors.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Emulate Inc: Emulate is the most directly comparable organ-on-chip vendor, offering its own chip platform (organ chips including Liver-Chip) and CRO services for pharma drug discovery, including extensive regulatory engagement (FDA collaborations) and partnerships with major pharma.
• TissUse GmbH: TissUse produces multi-organ-on-chip systems (e.g., HUMIMIC chips) for drug testing and toxicology, with both chips and services, competing in the same microphysiological-systems category as AIM Biotech.
• CN Bio Innovations: CN Bio develops microphysiological systems (Liver-Chip, Lung-Chip, and multi-organ MPS) and provides a PhysioMimix contract research service for pharma, directly overlapping AIM Biotech's MPS products and CRO business.
• Mimetas: Mimetas sells the OrganoPlate platform for 3D organ-on-a-chip and organoid-based assays, targeting pharma and academic drug discovery customers with microfluidic plates and CRO services, closely paralleling AIM's idenTx offering.

Emerging players

• NETRI: NETRI develops neuro-organ-on-chip and microfluidic compartmentalized neuron culture devices for neuroscience drug discovery, partially overlapping AIM's neurobiology / BBBBoost use cases.
• InSphero AG: InSphero develops 3D organoid and spheroid-based in vitro models for liver and toxicology testing, with services and consumables. It overlaps with AIM's organoid use cases but uses a static plate format rather than microfluidic chips.
• Hesperos Inc: Hesperos offers multi-organ microphysiological systems and contract research services for pharma toxicology and disease modeling, overlapping with AIM's idenTx and organiX platforms and contract research offering, though with a smaller commercial footprint.
• Nortis (formerly Neurofluidics): Nortis produces microfluidic organ-on-chip platforms for kidney, vasculature, and BBB modeling with associated contract services, offering a niche overlap with AIM's idenTx and BBBBoost products.

Others

• OrganaBio: OrganaBio supplies human cells, organoids, and tissue models for drug discovery, complementing AIM's MPS platforms with the cellular inputs and serving adjacent biomedical customers.
• MatTek Life Sciences: MatTek produces in vitro 3D tissue models (e.g., EpiDerm, EpiOcular) used for safety and efficacy testing and is also an AIM Biotech partner on advanced 3D tissue culture systems, making it both a complementary supplier and a partner.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AIMBiotech
• Facebookfacebook.com/aimbiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIM Biotech